瑞舒伐他汀隔日与每日治疗对血脂异常患者血脂及炎症标志物的影响

目的研究瑞舒伐他汀隔日给药10mg与每日给药10mg对血脂异常患者的血脂和炎症标志物的治疗差异。方法将37例患者随机分为2组,分别接受瑞舒伐他汀隔日给药10mg(N=19)和每日给药10mg(N=18)治疗6周后,比较用药前后血清中的低密度脂蛋白胆固醇(LDL-C),和血浆中C-反应蛋白(CRP)、白细胞介素-6(IL-6)的浓度变化。结果服药6周后,隔日治疗组和每日治疗组患者血清LDL-C、CRP、IL-6浓度与治疗前相比均有明显下降,高密度脂蛋白胆固醇和甘油三酯均有明显改善,但治疗效果两组间相比无统计学差异(P>0.05)。结论 10mg瑞舒伐他汀隔日治疗和每日治疗能同样有效改善中国患者的血脂和炎性标记物水平。

Effects of rosuvastatin daily or alternate-day on lipid profile and inflammatory markers

Background Statins are commonly administrated daily, while rosuvastatin can be given every other day due to its longer half-lives. We evaluated the potential efficacy of alternate-day dosing of 10 mg rosuvastatin compared with daily dosing of 10 mg rosuvastatin with regarding to lipid and inflammatory markers in patients with dyslipidemia. Methods Thirty-seven patients were randomly divided into the 2 groups： alternate-day group （rosuvastatin 10 mg every other day, n=19） and once-daily group （rosuvastatin 10 mg every day, n=18） for 6 weeks. The primary endpoints of the study were changes of the serum concentrations of low-density lipoprotein choles-terol （LDL-C）, C-reactive protein （CRP） and interleukin-6 （IL-6） following 6-week rosuvastatin therapy. Results Baseline characteristics of the 2 groups were well balanced. LDL-C decreased by 37.5% after the once-daily dosing period and by 36.9% after alternate-day dosing period （p〈0.05）. Both dosing regimens provided similar improvement in highdensity lipoprotein cholesterol and triglyceride. And also, both dosing regimens significantly decreased serum concentrations of CRP, which had an 18.3% reduction in once-daily dosing and a 16.7% reduction in alternate-day dosing of rosuvastatin （p〈0.05）. Moreover, the pattern of plasma IL-6 concentrations was also similar between the two groups （p〈0.05）. Conclusions Alternate-day dosing of rosuvastatin could be effective comparable with once-daily dosing of rosuvastatin in Chinese patients in improving not only lipid profile but also inflammatory markers, which may provide some cost savings and increase the compliance of patients.